STOCK TITAN

Titan Medical Announces Executive Departure

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) announced the immediate departure of Perry Genova, Senior Vice President of Research and Product Development, as it shifts focus from technology R&D to regulatory clearance and commercialization. Interim President Paul Cataford noted that the company's evolving needs necessitated this change. Titan Medical continues to develop the Enos™ robotic single access surgical system, which aims to enhance surgical procedures with ergonomic design for gynecologic indications. The company operates in Toronto and Chapel Hill, North Carolina.

Positive
  • Transitioning to a focus on regulatory clearance and commercialization, which could enhance market positioning.
  • Ongoing development of the Enos™ robotic surgical system aimed at improving surgical experiences.
Negative
  • Immediate departure of a senior executive may indicate instability during the transition phase.

TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced, after careful consideration and a review of the company’s future needs, that Perry Genova, Senior Vice President of Research and Product Development, will depart the company effective immediately.

“As we transform from a technology research and development company to a company focused on regulatory clearance and commercialization, our needs continue to evolve,” said Paul Cataford, Interim President, CEO and Board Chair. “We wish Perry success in his future endeavors.“

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the company’s future growth, results of operations, performance, and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the company’s focus on the design and development of surgical technologies for robotic single access surgery; the Enos system providing a surgical experience that imitates real-life movements; and the company’s intention to initially pursue gynecologic surgical indications with the Enos system. These statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Report for the fiscal year ended December 31, 2021, which may be viewed at www.sedar.com and at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Kristen Galfetti

Vice President, Investor Relations & Corporate Communications

+1-781-869-2553

investors@titanmedicalinc.com

Source: Titan Medical Inc.

FAQ

What recent leadership change occurred at Titan Medical (TMDI)?

Perry Genova, Senior Vice President of Research and Product Development, departed effective immediately.

Why did Titan Medical (TMDI) announce a leadership change?

The company is transitioning from technology R&D to a focus on regulatory clearance and commercialization.

What is the focus of Titan Medical's (TMDI) development efforts?

Titan Medical is developing the Enos™ robotic single access surgical system for gynecologic surgical indications.

Where is Titan Medical (TMDI) headquartered?

Titan Medical is headquartered in Toronto, Ontario.

What does the Enos™ system by Titan Medical (TMDI) aim to achieve?

The Enos™ system aims to improve surgical experiences by mimicking real-life movements with multi-articulating instruments.

TMDI

NASDAQ:TMDI

TMDI Rankings

TMDI Latest News

TMDI Stock Data

16.07M
111.59M
0.08%
4.56%
0.05%
Medical Devices
Healthcare
Link
Canada
Toronto